Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063558 | 0.83 | NR4A2 (0.71) | MAPTL3MBTL1CRHR1NR4A2LMNA | |
| SCHEMBL7697568 | 0.81 | ENPP3 (0.46) | MAPTL3MBTL1CRHR1NR4A2SMN1; SMN2 | |
| SCHEMBL318514 | 0.81 | MAPT (0.64) | MAPTL3MBTL1CRHR1NR4A2SMN1; SMN2 | |
| SCHEMBL2284354 | 0.81 | KDM4E (0.62) | MAPTL3MBTL1CRHR1NR4A2SMN1; SMN2 | |
| SCHEMBL5249809 | 0.79 | MAPT (0.57) | MAPTL3MBTL1NR4A2SMN1; SMN2GAA | |
| SCHEMBL439824 | 0.79 | NR4A2 (0.65) | MAPTL3MBTL1NR4A2SMN1; SMN2GAA | |
| SCHEMBL3051550 | 0.79 | MAPT (0.60) | MAPTL3MBTL1CRHR1NR4A2LMNA | |
| SCHEMBL661993 | 0.79 | MAPT (0.60) | MAPTL3MBTL1CRHR1NR4A2LMNA | |
| SCHEMBL461099 | 0.78 | MAPT (0.69) | MAPTL3MBTL1CRHR1NR4A2GAA | |
| SCHEMBL10005935 | 0.77 | MAPT (0.72) | MAPTL3MBTL1CRHR1NR4A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649110-B1 | MYCOBACTERIUM-TUBERCOLOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS ANTITUBERCULOSIS DRUG | UNIV DORTMUND TECH (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3649110-A1 | MYOBACTERIUM TUBERCULOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS AN ANTITUBERCULAR AGENT | Technische Universität Dortmund (DE) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019007710-A1 | MYOBACTERIUM TUBERCULOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS AN ANTITUBERCULAR AGENT | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2019-01-10 | — | — | WO | disclosed |
| EP-3424906-A1 | MYCOBACTERIUM-TUBERCOLOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS ANTITUBERCULOSIS DRUG | Technische Universität Dortmund (DE) | 2019-01-09 | — | — | EP | disclosed |
| WO-2017198756-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-23 | — | — | WO | disclosed |
| EP-3246028-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-0966442-B1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | DUPHAR INT RES (NL) | 2006-12-20 | — | — | EP | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| US-6350750-B1 | TREATMENT OF STRESS-RELATED DISORDERS; ARYLATION WITH BORONIC ACID DERIVATIVE, AMINATION | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2002-02-26 | — | — | US | disclosed |
| EP-0966442-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999012908-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | MAPT 2642/4885L3MBTL1 4386/4885CRHR1 74/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | MAPT 4719/4885L3MBTL1 4455/4885CRHR1 49/4885 |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | MAPT 2051/4885L3MBTL1 4811/4885CRHR1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.